NCT02609984 - Atezolizumab vs Atezolizumab + CMB305 & Synovial Sarcoma (SS) (NY-ESO-1 +) / Myxoid liposarcoma (NY-ESO-1 +)

Although the combination of CMB305 and atezolizumab did not result in significant increases in PFS or OS compared with atezolizumab alone, some patients demonstrated evidence of an anti-NY-ESO-1 immune response and appeared to fare better by imaging than those without such an immune response. Combining prime-boost vaccines such as CMB305 with anti–programmed death ligand-1 therapies merits further evaluation in other clinical contexts.
Chawla et al. 2022 J Clin Oncol 40: 1291-1300
…